Alzheimer's Disease Preclinical Research Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Transgenic Mouse Models of Alzheimer's Disease

Inquiry

At Ace Therapeutics, our preclinical research division is dedicated to advancing Alzheimer's disease (AD) studies through innovative modeling approaches. We employ transgenic mouse systems that recapitulate critical pathological processes, offering researchers robust platforms to investigate amyloid-beta dynamics, tau protein behavior, and neuroimmune interactions. Our models are specifically designed to bridge the gap between basic research and therapeutic development for both familial and sporadic AD subtypes.

Understanding Alzheimer's Pathology Through Transgenic Models

Alzheimer's disease manifests through three core pathological markers: amyloid-beta plaque deposition, neurofibrillary tangles containing hyperphosphorylated tau proteins, and progressive synaptic failure. Our transgenic models achieve unprecedented fidelity in replicating these hallmarks through:

Multi-gene integration (APP, PS1, tau mutations)
Age-dependent pathology development
Humanized disease progression timelines

The 5xFAD model exemplifies this approach, incorporating five distinct mutations to accelerate amyloid plaque formation for time-sensitive preclinical trials.

Model	Genetic Profile	Key Applications
APP/PS1	Dual APP/PS1 mutations	Amyloid cascade studies
5xFAD	5× amyloid pathway mutations	Early-onset AD drug screening
3xTg-AD	APP/PS1/tau triple mutation	Tau-amyoid interaction research
LOAD-Sim	APOE4 + environmental stressors	Sporadic AD modeling

Comprehensive Phenotyping Protocols

Our characterization platform combines behavioral analysis with cellular pathology assessment

Cognitive Tests

Radial arm maze navigation testing
Morris water maze spatial mapping
Fear conditioning memory assays

Neuroinflammatory Profiling

Microglial morphology quantification (Iba1+ cells)
Cytokine panel analysis (IL-1β, TNF-α, IL-6)
Astrocyte activation monitoring (GFAP expression)

Synaptic Integrity Metrics

Dendritic spine density (Golgi-Cox staining)
Synaptophysin/PDS95 immunoblotting
Electrophysiological LTP recordings

Genetic Risk Factor Modeling

We provide specialized models to investigate

APOE4 isoform effects on amyloid clearance
Presenilin mutations (PS1 M146V, PS2 N141I)
Tau isoform ratios (3R/4R tau balance)
GWAS-identified risk alleles (TREM2, CD33)

Therapeutic Development Support

Our preclinical testing platform evaluates

Amyloid-targeting biologics: Anti-Aβ monoclonal antibodies
Tau modulators: Kinase inhibitors, aggregation blockers
Neuroimmune regulators: Microglial repolarization agents

All trials include longitudinal PET/MRI imaging and CSF biomarker tracking aligned with clinical trial protocols.

Custom Model Engineering

Beyond standard models, we develop tailored systems featuring

Inducible gene expression (Tet-On/Off systems)
Cell-type specific promoters (Neuron/Glia-targeted)
Humanized gene replacements (APP Swedish mutation)

Why Choose Ace Therapeutics?

Multi-omics integration (Transcriptomic/Proteomic)
Cross-species validation (Mouse-Primate concordance studies)
In-depth phenotyping of cognitive deficits, synaptic loss, and neuroimmune interactions
Comprehensive genetic analysis of familial and sporadic AD models

For protocol customization or model development inquiries, contact our AD modeling specialists today to learn how Ace Therapeutics can accelerate your Alzheimer's drug discovery.

Our products and services are for research use only and can not be used for diagnostic or other purposes.